131 related articles for article (PubMed ID: 38873428)
1. Osteogenic mechanism of chlorogenic acid and its application in clinical practice.
Shen J; Zhang S; Zhang J; Wei X; Wang Z; Han B
Front Pharmacol; 2024; 15():1396354. PubMed ID: 38873428
[TBL] [Abstract][Full Text] [Related]
2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotective Roles of Green Tea Catechins.
Huang HT; Cheng TL; Lin SY; Ho CJ; Chyu JY; Yang RS; Chen CH; Shen CL
Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33207822
[TBL] [Abstract][Full Text] [Related]
5. Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts.
Lee DW; Kwon JY; Kim HK; Lee HJ; Kim ES; Kim HJ; Kim HJ; Lee HB
Int J Med Sci; 2018; 15(7):723-729. PubMed ID: 29910677
[TBL] [Abstract][Full Text] [Related]
6. miR-99a in bone homeostasis: Regulating osteogenic lineage commitment and osteoclast differentiation.
Moura SR; Bras JP; Freitas J; Osório H; Barbosa MA; Santos SG; Almeida MI
Bone; 2020 May; 134():115303. PubMed ID: 32126314
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
11. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
[TBL] [Abstract][Full Text] [Related]
12. Staphylococcus aureus biofilms decrease osteoblast viability, inhibits osteogenic differentiation, and increases bone resorption in vitro.
Sanchez CJ; Ward CL; Romano DR; Hurtgen BJ; Hardy SK; Woodbury RL; Trevino AV; Rathbone CR; Wenke JC
BMC Musculoskelet Disord; 2013 Jun; 14():187. PubMed ID: 23767824
[TBL] [Abstract][Full Text] [Related]
13. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β.
Ignatius A; Schoengraf P; Kreja L; Liedert A; Recknagel S; Kandert S; Brenner RE; Schneider M; Lambris JD; Huber-Lang M
J Cell Biochem; 2011 Sep; 112(9):2594-605. PubMed ID: 21598302
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.
Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G
J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
16. Methanolic extract of O.umbellata L. exhibits anti-osteoporotic effect via promoting osteoblast proliferation in MG-63 cells and inhibiting osteoclastogenesis in RANKL-stimulated RAW 264.7 cells.
Paramasivam S; Perumal SS
J Ethnopharmacol; 2023 Oct; 315():116641. PubMed ID: 37236379
[TBL] [Abstract][Full Text] [Related]
17. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
18. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview.
Wang LT; Chen LR; Chen KH
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982891
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Factor-Kappa B Regulation of Osteoclastogenesis and Osteoblastogenesis.
Boyce BF; Li J; Yao Z; Xing L
Endocrinol Metab (Seoul); 2023 Oct; 38(5):504-521. PubMed ID: 37749800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
